Is CRISPR Therapeutics the Best Gene-Editing Stock Right Now? Posted by Genevieve Klien in biotech/medical, genetics Nov 272019 Following strong results for its flagship CTX001 drug, should you add CRISPR to your portfolio? Read more | >
